03:55 PM EST, 11/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Our 12-month target price of $48, cut $2, reflects a combination of relative valuation and DCF model analyses. On a relative basis, we apply a 5.6x multiple of enterprise value to projected 2026 EBITDA, in line with OXY's recent historical forward average. That approach yields a value of $47 per share. Meanwhile, our DCF model, using free cash flow growth of 4% per year for 10 years, 2% thereafter, discounted at a WACC of 7.2%, yields a value of $49 per share. We cut our 2025 EPS estimate by $0.07 to $2.34 and 2026's by $0.57 to $2.40. The pricing outlook is not especially optimistic for liquids, but getting better for natural gas, and the company is making strides on debt reduction. Net debt to capital, now at 40%, still has a ways to go to get in line with peers (27%), but the upcoming sale of OxyChem for $9.7 billion in cash will go a long way on that front. Shares also yield 2.3%.